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kidneys, although brain and lung cul-
tures were negative.
Another group of guinea pigs that
had also been injected with Leptospira
was humanely killed as soon as symp-
toms appeared. Necropsy showed pri-
mary lung injury. Lungs were pale
with hemorrhages widely spread over
the surface. Lesions were similar to
those observed in one of the patients.
Neither jaundice nor renal damage
was found. Leptospira was isolated
from kidneys, lungs, and brain. Jaun-
dice has been reported in severe forms
of human disease. Thrombocytopenia
has been associated with renal failure
and death in human patients.
Respiratory involvement in lep-
tospirosis could be classified as a) mild
to moderate (20% to 70% of patients),
with pulmonary infiltrates commonly
associated with jaundice and minimal
alteration of renal function; b) severe,
with jaundice, nephropathy, hemor-
rhages (severe Weil's syndrome) (4),
and occasional death due to renal fail-
ure, myocarditis, or massive hemor-
rhages with cardiovascular collapse;
and c) pulmonary hemorrhage which is
frequently fatal, without jaundice,
nephropathy, or other hemorrhages.
In the past two decades, an
increasing number of cases of lep-
tospiral pulmonary hemorrhages have
been reported, especially from South-
east Asia (5). In a review of lep-
tospirosis in Brazil, death was
associated with renal failure in 76.2%
of fatal cases, while 3.5% were related
to pulmonary hemorrhages (6). In the
epidemic outbreak in Nicaragua in
1995, this form was considered the
cause of death in the 40 fatal cases
reported (7).
The two cases reported here were
associated with pulmonary hemor-
rhage. This clinical form has not been
previously reported in the Buenos
Aires metropolitan area. Environmen-
tal and social factors, the prevalence
of infection in reservoirs, and the viru-
lence of the isolated strains must be
considered in primary or critical-care
units in the diagnosis of new cases,
whether or not associated with an out-
break.
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To the Editor: On October 21,
2000, a previously healthy 25-year-old
male farmer was admitted to a mission
hospital in western Kenya with an
acute hemorrhagic illness. Four days
before admission, the patient had rapid
onset of fever, headache, nausea, vom-
iting, severe muscle pains, and diar-
rhea, which became bloody. On
admission his temperature was
36.4°C, pulse was 60/minute, respira-
tory rate was 20/minute, and blood
pressure was 90/40 mm Hg. In addi-
tion to the signs and symptoms listed
above, the only other abnormal find-
ing on admission was neck stiffness.
The differential diagnoses included
bacterial dysentery and meningitis.
Results of a blood smear for malaria
parasites and Widal test for typhoid
were negative, and cerebrospinal fluid
and urine examinations were normal.
The patient was treated with doxy-
cycline, cotrimoxazole, metronida-
zole, and intravenous fluids. On the
day after admission, the patient’s vom-
itus became blood stained and blood
was passed rectally. The patient was
isolated and strict barrier nursing
implemented on the suspicion of viral
hemorrhagic fever (VHF). Progressive
hypotension developed, resistant to
resuscitation efforts with intravenous
fluids and corticosteroids, and later
massive bleeding from the nose,
mouth, and upper and lower gas-
trointestinal tract occurred. The
patient died on the second day of
admission, 6 days after onset of ill-
ness. A serum sample was sent to the
Arbovirus and Viral Hemorrhagic
Fever Reference Laboratory in
Nairobi for diagnostic screening.
Serologic tests in Nairobi were
negative for yellow fever, dengue,
West Nile, Chikungunya, and Rift Val-
ley fever (immunoglobulin [Ig] M–LETTERS
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capture enzyme-linked immunosor-
bent assay) and reverse transcriptase-
polymerase chain reaction (RT-PCR)
tests for flaviviruses, alphaviruses,
and Bunyamwera serogroup bunyavi-
ruses were also negative. RT-PCR for
Crimean-Congo hemorrhagic fever
virus (C-CHFV) was positive. Tests
for anti-C-CHFV–specific IgM anti-
body by indirect immunofluorescence
were negative. Virus isolation
attempts were then terminated because
the cultivation of C-CHFV (the pre-
sumptive cause) requires biosafety
level 4 facilities. The specimen was
submitted to the Special Pathogens
Unit in Johannesburg for confirmation
of the result. The sample was positive
by RT-PCR for C-CHFV and was IgM
and IgG antibody negative. No isola-
tion of the virus could be made from
the serum sample, possibly because it
was received by the Johannesburg lab-
oratory 8 days after initial collection
and following freeze-thaw conditions.
The specimen was insufficient to
attempt C-CHVF antigen detection
assays. Sequencing of the RT-PCR
amplicon confirmed C-CHFV.
C-CHFV is a tick-borne virus of
the genus Nairovirus, family Bun-
yaviridae, and is widely distributed
throughout eastern Europe and the
Crimea, to the Middle East and west-
ern China, Pakistan, and Africa. Natu-
ral hosts for this virus are varied
(including wild and domestic animals
and birds) and may reflect the feeding
preferences of the host tick (1). While
C-CHFV infections are rare in
humans, the virus is notorious for
nosocomial outbreaks of VHF, typi-
cally following admission of an index
case to a health-care facility where
VHF was not suspected, with mortal-
ity rates up to 40%. 
Previous evidence for C-CHFV in
Kenya is limited and based on serol-
ogy (human and bovine) and two iso-
lations of C-CHFV from non-human
sources (1,2). This report represents
the first documented case of acute
human C-CHFV infection in Kenya.
The hospital concerned belongs to a
VHF surveillance network serving to
increase awareness and preparedness
within Kenyan health-care facilities.
In this case suspicion of VHF was
raised, and the patient was immedi-
ately isolated, noninvasive procedures
were instigated, and barrier nursing
was implemented to prevent nosoco-
mial transmission. No family or hospi-
tal staff member who had close
contact with the patient became ill.
Although VHFs are rare, this report
stresses the need for health facilities in
Kenya and East/Central Africa to
include VHFs in their differential
diagnosis of unexplained fever with
hemorrhagic tendencies, as well as the
utility of the surveillance network.
The causative agents of Ebola hemor-
rhagic fever, Marburg hemorrhagic
fever, C-CHFV, Rift Valley fever, and
yellow fever are all endemic in East
and Central Africa, and sporadic
cases, as well as outbreaks, are likely
to continue to occur in this region
(3–5).
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Preparing at the 
Local Level for 
Events Involving 
Weapons of Mass 
Destruction
To the Editor: The use of hi-
jacked airplanes in the attacks on the
World Trade Center and the Pentagon
on September 11, 2001, clearly illus-
trated the immediate and massive
destruction that can result from a well-
orchestrated, long-planned, and pur-
poseful terrorist act. Weapons of mass
destruction (WMD) events (i.e., bio-
logical, nuclear, or chemical attacks)
present different challenges than other
incidents involving mass casualties
(e.g., chemical spills, transportation
mishaps, or natural disasters). Persons
involved in a biological weapons
attack, for example, may take days to
develop symptoms and seek medical
care (1); a large geographic area may
be affected, or persons may travel long
distances and unwittingly infect oth-
ers, including hospital personnel (2).
Furthermore, traditional hazardous
materials and emergency medical pro-
cedures may be inadequate to respond
to a WMD event (3–5). As events of
September 11 and its aftermath make
clear, medical public health systems
were not optimally prepared. An
effective response to a WMD event
focuses on two key areas: joint efforts
between the medical community and
public health agencies and better
trained and coordinated first respond-
ers (i.e., law enforcement, public
safety, hospital personnel, and public
health officials) (1–3).  
In early 2001, telephone inter-
views with West Virginia county
health directors (CHDs) or their
equivalent were conducted to ascer-
1Dr. Kazooba-Voskamp, the attending phy-
sician in this case, has requested that the
hospital’s identity remain anonymous.